Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Effect of aberrant p53 function on temozolomide sensitivity of glioma cell lines and brain tumor initiating cells from glioblastoma.

Journal of neuro-oncology - 1 Mar 2011

Blough Michael D, Beauchamp Desiree C, Westgate Morgan R, Kelly John J, Cairncross J Gregory

Abstract excerpt

The most effective chemotherapeutic for glioblastoma (GBM) is the DNA alkylating agent temozolomide (TMZ). In a recent study by Hegi et al. benefit from TMZ was significantly associated with methylation of the promoter of the O6-methylguanine-DNA methyltransferase (MGMT) gene; however, the correlation was imperfect. Some patients with methylated tumors were short survivors and others with unmethylated tumors were...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents, Alkylating
Share to Brain Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Dacarbazine

Share to Glioma

Share to Neoplastic Stem Cells

Share to O(6)-Methylguanine-DNA Methyltransferase

Share to RNA, Small Interfering

Share to Temozolomide

Source

Identifiers

PMID: 20593219
DOI: 10.1007/s11060-010-0283-9

Genes

MGMT

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Effect of aberrant p53 function on temozolomide sensitivity of glioma cell lines and brain tumor initiating cells from glioblastoma.PMID 20593219Read ↗

Gain of function of mutant TP53 in glioblastoma: prognosis and response to temozolomide.Semantic proximity Read ↗

Sensitivity to temozolomide in brain tumor initiating cellsSemantic proximity Read ↗

Mutant TP53 enhances the resistance of glioblastoma cells to temozolomide by up-regulating O(6)-methylguanine DNA-methyltransferase.Semantic proximity Read ↗

<i>O6-Methylguanine-DNA Methyltransferase</i> Regulation by p53 in Astrocytic CellsSemantic proximity Read ↗

Multifaceted resistance of gliomas to temozolomide.Semantic proximity Read ↗

Temozolomide resistance in glioblastoma multiformeSemantic proximity Read ↗

Sensitivity to temozolomide of cell lines derived from brain tumours and melanomas: relationship to MGMT gene expressionSemantic proximity Read ↗

Temozolomide Resistance in Glioblastoma Cell Lines: Implication of MGMT, MMR, P-Glycoprotein and CD133 ExpressionSemantic proximity Read ↗

MEK-ERK Signaling Dictates DNA-Repair Gene MGMT Expression and Temozolomide Resistance of Stem-Like Glioblastoma Cells via the MDM2-p53 AxisSemantic proximity Read ↗

Acquired Resistance to Temozolomide in Glioma Cell Lines: Molecular Mechanisms and Potential Translational ApplicationsSemantic proximity Read ↗

p53 disruption profoundly alters the response of human glioblastoma cells to DNA topoisomerase I inhibitionSemantic proximity Read ↗

A combination of IFN-β and temozolomide in human glioma xenograft models: implication of p53-mediated MGMT downregulationSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.